BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Seesuay W, Jittavisutthikul S, Sae-Lim N, Sookrung N, Sakolvaree Y, Chaicumpa W. Human transbodies that interfere with the functions of Ebola virus VP35 protein in genome replication and transcription and innate immune antagonism. Emerg Microbes Infect 2018;7:41. [PMID: 29568066 DOI: 10.1038/s41426-018-0031-3] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 4.8] [Reference Citation Analysis]
Number Citing Articles
1 Mohammad MHS. Immune response scenario and vaccine development for SARS-CoV-2 infection. Int Immunopharmacol 2021;94:107439. [PMID: 33571745 DOI: 10.1016/j.intimp.2021.107439] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
2 Baral PK, Yin J, James MNG. Treatment and prevention strategies for the COVID 19 pandemic: A review of immunotherapeutic approaches for neutralizing SARS-CoV-2. Int J Biol Macromol 2021;186:490-500. [PMID: 34237371 DOI: 10.1016/j.ijbiomac.2021.07.013] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Flego M, Frau A, Accardi L, Mallano A, Ascione A, Gellini M, Fanunza E, Vella S, Di Bonito P, Tramontano E. Intracellular human antibody fragments recognizing the VP35 protein of Zaire Ebola filovirus inhibit the protein activity. BMC Biotechnol 2019;19:64. [PMID: 31488108 DOI: 10.1186/s12896-019-0554-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
4 Hozhabri H, Piceci Sparascio F, Sohrabi H, Mousavifar L, Roy R, Scribano D, De Luca A, Ambrosi C, Sarshar M. The Global Emergency of Novel Coronavirus (SARS-CoV-2): An Update of the Current Status and Forecasting. Int J Environ Res Public Health 2020;17:E5648. [PMID: 32764417 DOI: 10.3390/ijerph17165648] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 7.5] [Reference Citation Analysis]
5 Dhama K, Khan S, Tiwari R, Sircar S, Bhat S, Malik YS, Singh KP, Chaicumpa W, Bonilla-Aldana DK, Rodriguez-Morales AJ. Coronavirus Disease 2019-COVID-19. Clin Microbiol Rev. 2020;33. [PMID: 32580969 DOI: 10.1128/cmr.00028-20] [Cited by in Crossref: 222] [Cited by in F6Publishing: 125] [Article Influence: 111.0] [Reference Citation Analysis]
6 Fierabracci A, Arena A, Rossi P. COVID-19: A Review on Diagnosis, Treatment, and Prophylaxis. Int J Mol Sci 2020;21:E5145. [PMID: 32708112 DOI: 10.3390/ijms21145145] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
7 Sadeghian I, Heidari R, Sadeghian S, Raee MJ, Negahdaripour M. Potential of cell-penetrating peptides (CPPs) in delivery of antiviral therapeutics and vaccines. Eur J Pharm Sci 2021;169:106094. [PMID: 34896590 DOI: 10.1016/j.ejps.2021.106094] [Reference Citation Analysis]
8 Slastnikova TA, Ulasov AV, Rosenkranz AA, Sobolev AS. Targeted Intracellular Delivery of Antibodies: The State of the Art. Front Pharmacol 2018;9:1208. [PMID: 30405420 DOI: 10.3389/fphar.2018.01208] [Cited by in Crossref: 61] [Cited by in F6Publishing: 58] [Article Influence: 15.3] [Reference Citation Analysis]
9 Roth KDR, Wenzel EV, Ruschig M, Steinke S, Langreder N, Heine PA, Schneider KT, Ballmann R, Fühner V, Kuhn P, Schirrmann T, Frenzel A, Dübel S, Schubert M, Moreira GMSG, Bertoglio F, Russo G, Hust M. Developing Recombinant Antibodies by Phage Display Against Infectious Diseases and Toxins for Diagnostics and Therapy. Front Cell Infect Microbiol 2021;11:697876. [PMID: 34307196 DOI: 10.3389/fcimb.2021.697876] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Owji H, Negahdaripour M, Hajighahramani N. Immunotherapeutic approaches to curtail COVID-19. Int Immunopharmacol 2020;88:106924. [PMID: 32877828 DOI: 10.1016/j.intimp.2020.106924] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 9.5] [Reference Citation Analysis]
11 Di Palma F, Daino GL, Ramaswamy VK, Corona A, Frau A, Fanunza E, Vargiu AV, Tramontano E, Ruggerone P. Relevance of Ebola virus VP35 homo-dimerization on the type I interferon cascade inhibition. Antivir Chem Chemother 2019;27:2040206619889220. [PMID: 31744306 DOI: 10.1177/2040206619889220] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
12 Fanunza E, Frau A, Corona A, Tramontano E. Insights into Ebola Virus VP35 and VP24 Interferon Inhibitory Functions and their Initial Exploitation as Drug Targets. Infect Disord Drug Targets 2019;19:362-74. [PMID: 30468131 DOI: 10.2174/1871526519666181123145540] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
13 Amatya P, Wagner N, Chen G, Luthra P, Shi L, Borek D, Pavlenco A, Rohrs H, Basler CF, Sidhu SS, Gross ML, Leung DW. Inhibition of Marburg Virus RNA Synthesis by a Synthetic Anti-VP35 Antibody. ACS Infect Dis 2019;5:1385-96. [PMID: 31120240 DOI: 10.1021/acsinfecdis.9b00091] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
14 Dash P, Mohapatra S, Ghosh S, Nayak B. A Scoping Insight on Potential Prophylactics, Vaccines and Therapeutic Weaponry for the Ongoing Novel Coronavirus (COVID-19) Pandemic- A Comprehensive Review. Front Pharmacol 2020;11:590154. [PMID: 33815095 DOI: 10.3389/fphar.2020.590154] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
15 Muralidar S, Ambi SV, Sekaran S, Krishnan UM. The emergence of COVID-19 as a global pandemic: Understanding the epidemiology, immune response and potential therapeutic targets of SARS-CoV-2. Biochimie 2020;179:85-100. [PMID: 32971147 DOI: 10.1016/j.biochi.2020.09.018] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 6.5] [Reference Citation Analysis]
16 Sheikhshahrokh A, Ranjbar R, Saeidi E, Safarpoor Dehkordi F, Heiat M, Ghasemi-Dehkordi P, Goodarzi H. Frontier Therapeutics and Vaccine Strategies for SARS-CoV-2 (COVID-19): A Review. Iran J Public Health 2020;49:18-29. [PMID: 34268202 DOI: 10.18502/ijph.v49iS1.3666] [Cited by in Crossref: 6] [Article Influence: 3.0] [Reference Citation Analysis]
17 Singh SP, Pritam M, Pandey B, Yadav TP. Microstructure, pathophysiology, and potential therapeutics of COVID-19: A comprehensive review. J Med Virol 2021;93:275-99. [PMID: 32617987 DOI: 10.1002/jmv.26254] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
18 Corona A, Fanunza E, Salata C, Morwitzer MJ, Distinto S, Zinzula L, Sanna C, Frau A, Daino GL, Quartu M, Taglialatela-scafati O, Rigano D, Reid S, Mirazimi A, Tramontano E. Cynarin blocks Ebola virus replication by counteracting VP35 inhibition of interferon-beta production. Antiviral Research 2022. [DOI: 10.1016/j.antiviral.2022.105251] [Reference Citation Analysis]
19 Darko LKS, Broni E, Amuzu DSY, Wilson MD, Parry CS, Kwofie SK. Computational Study on Potential Novel Anti-Ebola Virus Protein VP35 Natural Compounds. Biomedicines 2021;9:1796. [PMID: 34944612 DOI: 10.3390/biomedicines9121796] [Reference Citation Analysis]
20 Sarwar Z, Ahmad T, Kakar S. Potential approaches to combat COVID-19: a mini-review. Mol Biol Rep 2020;47:9939-49. [PMID: 33185828 DOI: 10.1007/s11033-020-05988-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
21 Dhama K, Sharun K, Tiwari R, Dadar M, Malik YS, Singh KP, Chaicumpa W. COVID-19, an emerging coronavirus infection: advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics. Hum Vaccin Immunother 2020;16:1232-8. [PMID: 32186952 DOI: 10.1080/21645515.2020.1735227] [Cited by in Crossref: 210] [Cited by in F6Publishing: 203] [Article Influence: 105.0] [Reference Citation Analysis]
22 Wirchnianski AS, Wec AZ, Nyakatura EK, Herbert AS, Slough MM, Kuehne AI, Mittler E, Jangra RK, Teruya J, Dye JM, Lai JR, Chandran K. Two Distinct Lysosomal Targeting Strategies Afford Trojan Horse Antibodies With Pan-Filovirus Activity. Front Immunol 2021;12:729851. [PMID: 34721393 DOI: 10.3389/fimmu.2021.729851] [Reference Citation Analysis]
23 Niamsuphap S, Fercher C, Kumble S, Huda P, Mahler SM, Howard CB. Targeting the undruggable: emerging technologies in antibody delivery against intracellular targets. Expert Opinion on Drug Delivery 2020;17:1189-211. [DOI: 10.1080/17425247.2020.1781088] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
24 Dhama K, Karthik K, Khandia R, Chakraborty S, Munjal A, Latheef SK, Kumar D, Ramakrishnan MA, Malik YS, Singh R, Malik SVS, Singh RK, Chaicumpa W. Advances in Designing and Developing Vaccines, Drugs, and Therapies to Counter Ebola Virus. Front Immunol 2018;9:1803. [PMID: 30147687 DOI: 10.3389/fimmu.2018.01803] [Cited by in Crossref: 38] [Cited by in F6Publishing: 32] [Article Influence: 9.5] [Reference Citation Analysis]